Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash from Financing Activities: 2012-2025

Historic Cash from Financing Activities for Fennec Pharmaceuticals (FENC) over the last 9 years, with Sep 2025 value amounting to $1.7 million.

  • Fennec Pharmaceuticals' Cash from Financing Activities rose 431.25% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.4 million, marking a year-over-year decrease of 340.07%. This contributed to the annual value of -$13.6 million for FY2024, which is 305.11% down from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Cash from Financing Activities is $1.7 million, which was up 715.85% from -$284,000 recorded in Q2 2025.
  • Fennec Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $19.8 million during Q3 2022, with a 5-year trough of -$12.2 million in Q4 2024.
  • Its 3-year average for Cash from Financing Activities is -$468,455, with a median of $201,000 in 2023.
  • In the last 5 years, Fennec Pharmaceuticals' Cash from Financing Activities spiked by 1,186.67% in 2023 and then crashed by 686.53% in 2024.
  • Fennec Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $5.0 million in 2021, then reached $824,000 in 2022, then surged by 595.39% to $5.7 million in 2023, then tumbled by 313.12% to -$12.2 million in 2024, then surged by 431.25% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, -$284,000 for Q2 2025, and $359,000 during Q1 2025.